Ausgabe 3/2005
Inhalt (10 Artikel)
A mutated p53 status did not prevent the induction of apoptosis by sulforaphane, a promising anti-cancer drug
Carmela Fimognari, Luca Sangiorgi, Silvia Capponcelli, Michael Nüsse, Silvia Fontanesi, Fausto Berti, Silvia Soddu, Giorgio Cantelli-Forti, Patrizia Hrelia
Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines
Frank Mayer, Sandra Mueller, Elke Malenke, M. Kuczyk, Jörg T. Hartmann, Carsten Bokemeyer
Cryptophycins-309, 249 and other cryptophycin analogs: Preclinical efficacy studies with mouse and human tumors
Jian Liang, Richard E. Moore, Eric D. Moher, John E. Munroe, Rima S. Al-awar, David A. Hay, David L. Varie, Tony Y. Zhang, James A. Aikins, Michael J. Martinelli, Chuan Shih, James E. Ray, Lowell L. Gibson, Vasu Vasudevan, Lisa Polin, Kathryn White, Juiwanna Kushner, Chiab Simpson, Susan Pugh, Thomas H. Corbett
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam
Charlotte van Kesteren, Anthe S. Zandvliet, Mats O. Karlsson, Ron A. A. Mathôt, Cornelis J. A. Punt, Jean-Pierre Armand, Eric Raymond, Alwin D. R. Huitema, Christian Dittrich, Herlinde Dumez, Henri H. Roché, Jean-Pierre Droz, Miroslav Ravic, S. Murray Yule, Jantien Wanders, Jos H. Beijnen, Pierre Fumoleau, Jan H. M. Schellens
Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy
Dean Lim, Robert J. Morgan Jr., Steven Akman, Kim Margolin, Brian I. Carr, Lucille Leong, Oluwole Odujinrin, James H. Doroshow
A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer
Heather Wakelee, George A. Fisher
Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer
M. Méndez, P. G. Alfonso, E. Pujol, E. González, C. Castañon, P. Cerezuela, Y. López-Mateos, J. J. Cruz
Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma
Michael J. Millward, Anthony Joshua, Rick Kefford, Steinar Aamdal, Damien Thomson, Peter Hersey, Guy Toner, Kevin Lynch
Phase II trial of dolastatin-10 in patients with advanced breast cancer
Edith A. Perez, David W. Hillman, Paul A. Fishkin, James E. Krook, Winston W. Tan, Phillip A. Kuriakose, Steven R. Alberts, Shaker R. Dakhil
Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer
Johan Vansteenkiste, Jean-Luc Canon, Henrik Riska, Robert Pirker, Patrick Peterson, William John, Pekka Mali, Michael Lahn